PharmaNutra SpA (PHN) AI Stock Analysis

• Market Cap: €610.87M
• Dividend Yield: 1.86%
• Average Volume (3M): 25.97K
• Price to Earnings (P/E): 34.5
• Beta (1Y): 0.47
• Revenue Growth: 12.82%
• EPS Growth: 7.37%
• Country: IT
• Employees: 118
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.50
• Shares Outstanding: 9,680,977
• 10 Day Avg. Volume: 12,507
• 30 Day Avg. Volume: 25,966
• PEG Ratio: 1.05
• Price to Book (P/B): 8.41
• Price to Sales (P/S): 4.50
• P/FCF Ratio: 32.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €82.33
• Price Target Upside: 68.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: €70.00 ▲(43.00% Upside)

PharmaNutra SpA's strong financial performance, characterized by robust revenue growth and stable profitability, is the most significant factor supporting the stock score. Positive technical indicators further bolster the score, indicating a favorable market trend. However, the relatively high P/E ratio suggests valuation concerns, slightly offsetting the overall score.

Positive Factors

High gross and net margins

Sustained high gross margins indicate strong pricing power and low variable costs, while a double-digit net margin shows overall business efficiency. These durable margin levels support ongoing R&D, marketing and expansion, and improve the company’s ability to self-fund growth over the next 2–6 months.

Moderate leverage and strong ROE

A low debt-to-equity ratio combined with a high ROE reflects conservative capital structure and effective use of equity. This balance provides financial flexibility for investments or downturns, reducing refinancing risk and supporting durable operational plans and strategic initiatives over the medium term.

Improving free cash flow

Material free cash flow growth enhances the company’s ability to fund capex, R&D and shareholder returns without relying on external financing. Improving cash generation strengthens liquidity and resilience, making business plans and expansion initiatives more sustainable over a 2–6 month horizon.

Negative Factors

Weak cash conversion

Earnings not fully converting into operating cash can signal working-capital pressure, timing mismatches or non-cash income items. Persisting shortfalls constrain reinvestment capacity and make the company more sensitive to supplier/customer payment cycles, posing a structural risk to cash-driven plans.

Margin pressure trend

A declining net margin, even if modest, can indicate rising input costs, pricing limits or increased operating expenses. If the trend continues, it will erode profitability and reduce retained earnings available for growth, making future margin recovery and investment harder over the medium term.

Product concentration risk

Heavy reliance on a few proprietary products creates concentration risk: regulatory changes, competitive entrants, or patent challenges could disproportionately reduce revenue. Diversification of the product portfolio or geographic mix is needed to mitigate this structural vulnerability over the coming months.

PharmaNutra SpA Business Overview & Revenue Model

Company Description

PharmaNutra SpA is an Italian pharmaceutical company specializing in the research, development, and commercialization of nutritional supplements and medical devices. The company operates primarily in the healthcare sector, focusing on innovative products that enhance human health and well-being. Its core offerings include iron-based supplements, minerals, and other nutritional products designed to address various health issues, particularly in the areas of sports nutrition, joint health, and women's health.

How the Company Makes Money

PharmaNutra SpA generates revenue through the sale of its nutritional supplements and medical devices across various markets, with a strong emphasis on both domestic and international sales. The company's revenue model is primarily based on direct sales to pharmacies, hospitals, and healthcare providers, as well as partnerships with distributors and retailers. Key revenue streams include proprietary products such as Sideral, a patented iron supplement, which has gained significant market traction. Additionally, PharmaNutra benefits from collaborations with research institutions and strategic partnerships that enhance product development and market reach, further contributing to its earnings.

PharmaNutra SpA Financial Statement Overview

Summary

PharmaNutra SpA demonstrates strong financial health with consistent revenue growth and solid profitability margins. The balance sheet is stable with moderate leverage, and cash flow generation is improving. While there are some areas for improvement, particularly in cash conversion, the overall financial position is robust, supporting future growth prospects.

Income Statement

PharmaNutra SpA shows strong revenue growth with a 4.14% increase in the TTM period. The company maintains healthy margins, with a gross profit margin of 74.34% and a net profit margin of 13.76% in the TTM. EBIT and EBITDA margins are also robust, indicating efficient operations. However, the slight decline in net profit margin compared to the previous year suggests some pressure on profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.36 in the TTM, indicating moderate leverage. The return on equity is strong at 27.39%, showcasing effective use of equity capital. However, the equity ratio is not explicitly provided, which limits a full assessment of asset financing.

Cash Flow

Cash flow analysis reveals a positive trajectory with a 27.22% growth in free cash flow in the TTM. The operating cash flow to net income ratio is below 1, suggesting some challenges in converting income into cash. The free cash flow to net income ratio of 0.67 indicates a moderate level of cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	127.88M	116.15M	101.03M	83.39M	68.14M	58.48M
Gross Profit	106.84M	82.79M	48.95M	30.17M	32.15M	21.30M
EBITDA	33.56M	32.01M	26.53M	24.61M	19.84M	14.28M
Net Income	17.45M	16.61M	12.83M	15.05M	13.77M	14.07M
Balance Sheet
Total Assets	119.77M	117.47M	112.44M	100.16M	71.36M	51.71M
Cash, Cash Equivalents and Short-Term Investments	21.96M	29.10M	25.12M	26.86M	33.94M	20.80M
Total Debt	20.98M	24.27M	28.02M	17.73M	6.35M	1.66M
Total Liabilities	53.70M	55.27M	58.04M	49.21M	26.27M	13.98M
Stockholders Equity	66.10M	62.16M	54.41M	50.95M	45.08M	37.73M
Cash Flow
Free Cash Flow	10.44M	16.25M	-1.16M	-8.69M	15.43M	10.46M
Operating Cash Flow	14.45M	20.50M	12.09M	14.47M	20.41M	11.79M
Investing Cash Flow	-3.07M	-2.21M	-14.70M	-23.71M	-5.54M	-598.00K
Financing Cash Flow	-14.43M	-21.59M	-516.00K	1.89M	-1.92M	-4.73M

PharmaNutra SpA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Positive. The current price of 48.95 is below the 20-day moving average (MA) of 60.74, below the 50-day MA of 56.64, and below the 200-day MA of 49.85, indicating a bullish trend. The MACD of 2.63 indicates Negative momentum. The RSI at 60.26 is Neutral, neither overbought nor oversold. The STOCH value of 56.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHN.

PharmaNutra SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHN	74 Outperform	€610.87M	34.49	―	1.86%	12.82%	7.37%
PHIL	70 Outperform	€614.10M	18.46	45.54%	―	3346.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%